ArticleInternational journal of ophthalmology2023
Clinical observation of recombinant human nerve growth factor in the treatment of neurotrophic keratitis.
Article in International journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS).Eye (London, England) · 2026Article
- AQP5 Regulates Corneal Nerve Distribution Through NETRIN-1 and SLIT3.Investigative ophthalmology & visual science · 2025Article
- Evaluation ofFrontiers in bioengineering and biotechnology · 2025Article
- Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO).Ophthalmology and therapy · 2024Article
- Small-diameter acellular porcine corneal stroma for peripheral corneal ulceration treatment.International journal of ophthalmology · 2024Article
- The use of rh-NGF in the management of neurotrophic keratopathy.Frontiers in ophthalmology · 2024Review
- Elucidating the mechanism of corneal epithelial cell repair: unraveling the impact of growth factors.Frontiers in medicine · 2024Review
- Hydrogel dressings on neurotrophic keratitis in an experimental animal model.International journal of ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo characterize changes of corneal nerve morphology and tear indices in patients with neurotrophic keratitis (NK) treated with recombinant human nerve growth factor (rhNGF).
methodsIn a prospective observational study, six patients (nine eyes) were locally treated with rhNGF. Visual acuity, corneal fluorescein staining score, the heights of the tear river, lipid layer thickness (LLT), tear ferning (TF) test, conjunctival impression cytology (CIC) examination, the densities of cornea subbasal nerve fibers were determined before and after treatment.
resultsCompared with baseline, there was a significant difference in corneal fluorescence staining scores (
conclusionRhNGF can increase the density of corneal subbasal nerve fibers, promote the healing of persistent corneal epithelial defects and corneal ulcers in patients with NK, also improving tear function partially.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.